within Pharmacolibrary.Drugs.ATC.C;

model C08EA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600,            
    Vdp             = 0.015,
    k12             = 0.9,
    k21             = 0.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08EA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bepridil is a nonselective calcium channel blocker, formerly used for the management of angina pectoris and arrhythmias such as atrial fibrillation. Due to safety concerns, notably QT prolongation and risk of torsades de pointes, it is no longer approved or widely used in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Benet, LZ (1985). Pharmacokinetics and metabolism of bepridil. <i>The American journal of cardiology</i> 55(7) 8C–13C. DOI:<a href=\"https://doi.org/10.1016/0002-9149(85)90799-4\">10.1016/0002-9149(85)90799-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3872057/\">https://pubmed.ncbi.nlm.nih.gov/3872057</a></p></li><li><p>Taguchi, M, et al., &amp; Hashimoto, Y (2006). Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. <i>Biological &amp; pharmaceutical bulletin</i> 29(3) 517–521. DOI:<a href=\"https://doi.org/10.1248/bpb.29.517\">10.1248/bpb.29.517</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16508157/\">https://pubmed.ncbi.nlm.nih.gov/16508157</a></p></li><li><p>Awni, WM, et al., &amp; Matzke, GR (1995). Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease. <i>Journal of clinical pharmacology</i> 35(4) 379–383. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1995.tb04077.x\">10.1002/j.1552-4604.1995.tb04077.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7650227/\">https://pubmed.ncbi.nlm.nih.gov/7650227</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08EA02;
